Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

OBJECTIVE: Oligomeric forms of amyloid β protein (oAβ) are believed to be principally responsible for neurotoxicity in Alzheimer disease (AD), but it is not known whether anti‐Aβ antibodies are capable of lowering oAβ levels in humans. METHODS: We developed an ultrasensitive immunoassay and used it...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ting, Dang, Yifan, Ostaszewski, Beth, Mengel, David, Steffen, Verena, Rabe, Christina, Bittner, Tobias, Walsh, Dominic M., Selkoe, Dennis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771589/
https://www.ncbi.nlm.nih.gov/pubmed/31168802
http://dx.doi.org/10.1002/ana.25513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771589/
https://www.ncbi.nlm.nih.gov/pubmed/31168802
http://dx.doi.org/10.1002/ana.25513

Ejemplares similares